|Articles|April 26, 2004

Proprietary sustained-release dexamethasone implant shows promise for treating persistent cystoid macular edema

Results of a controlled Phase I/II study show that the bioerodable, sustained-release,dexamethasone implant (Posurdex, Allergan) results in a statistically significantincrease in ETDRS standardized visual acuity in eyes with persistent cystoidmacular edema (CME), said Mark S. Blumenkranz, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME